About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Notes to editors 

The Select Committee on the Long-term Sustainability of the NHS was appointed by the House of Lords on 25 May 2016 to consider the long-term sustainability of the National Health Service.​ 

View the full report 'The Long-term Sustainability of the NHS and Adult Social Care' online.

ABPI submitted written evidence to the Committee.​​

Media enquiries

+44 (0) 20 7747 7147​​